Effect of high-dose oral N-acetylcysteine versus placebo on serum level of inflammatory cytokines in patients with ischemic stroke

Effect of high-dose oral N-acetylcysteine versus placebo on serum level of inflammatory cytokines in patients with ischemic stroke: a double-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N215

Enrollment

100

Registered

2018-03-19

Start date

2018-04-20

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke. Cerebral infarction

Interventions

Intervention 1: Intervention group: Routine stroke treatment plus oral N-acetylcysteine tablet (manufactured by Hexal Pharmaceutical Co.) with a loading dose of 4 g and then 2 g every 12 hours for 2 d

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 85 years Ischemic stroke Stroke for the first time Local neurologic disorder Hospitalization within the first 24 hours after stroke

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Inflammatory disease Asthma A history of anaphylaxis shock

Design outcomes

Primary

Measure	Time frame
Measuring serum level of TNF-a. Timepoint: Before intervention and 3 days later. Method of measurement: Through laboratory test.;Measuring serum level of IL-6. Timepoint: Before intervention and 3 days later. Method of measurement: Through laboratory test.;Measuring serum level of ICAM-1. Timepoint: Before intervention and 3 days later. Method of measurement: Through laboratory test.;Measuring serum level of NSE. Timepoint: Before intervention and 3 days later. Method of measurement: Through laboratory test.	—

Measure

Time frame

Measuring serum level of TNF-a. Timepoint: Before intervention and 3 days later. Method of measurement: Through laboratory test.;Measuring serum level of IL-6. Timepoint: Before intervention and 3 days later. Method of measurement: Through laboratory test.;Measuring serum level of ICAM-1. Timepoint: Before intervention and 3 days later. Method of measurement: Through laboratory test.;Measuring serum level of NSE. Timepoint: Before intervention and 3 days later. Method of measurement: Through laboratory test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Maryam Mehrpoya

Hamedan University of Medical Sciences

m_mehrpooya2003@yahoo.com+98 81 3827 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026